OA10716A - Ligands for flt3 receptors - Google Patents

Ligands for flt3 receptors Download PDF

Info

Publication number
OA10716A
OA10716A OA60744A OA60744A OA10716A OA 10716 A OA10716 A OA 10716A OA 60744 A OA60744 A OA 60744A OA 60744 A OA60744 A OA 60744A OA 10716 A OA10716 A OA 10716A
Authority
OA
OAPI
Prior art keywords
flt3
cells
polypeptide
csf
patient
Prior art date
Application number
OA60744A
Other languages
English (en)
Inventor
Stewart D Lyman
Patricia M Beckmann
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of OA10716A publication Critical patent/OA10716A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
OA60744A 1993-05-24 1995-11-21 Ligands for flt3 receptors OA10716A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6839493A 1993-05-24 1993-05-24
US10646393A 1993-08-12 1993-08-12
US11175893A 1993-08-25 1993-08-25
US16240793A 1993-12-03 1993-12-03
US20950294A 1994-03-07 1994-03-07

Publications (1)

Publication Number Publication Date
OA10716A true OA10716A (en) 2002-12-09

Family

ID=27535798

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60744A OA10716A (en) 1993-05-24 1995-11-21 Ligands for flt3 receptors

Country Status (16)

Country Link
US (3) US5554512A (fr)
JP (1) JP4028594B2 (fr)
KR (1) KR100319359B1 (fr)
CN (1) CN1123574C (fr)
AU (1) AU683472B2 (fr)
BR (1) BR9407073A (fr)
CA (1) CA2162397C (fr)
FI (1) FI955646A (fr)
HU (1) HUT74831A (fr)
MY (1) MY148148A (fr)
NO (1) NO322373B1 (fr)
NZ (1) NZ267541A (fr)
OA (1) OA10716A (fr)
PL (1) PL311756A1 (fr)
UA (1) UA42726C2 (fr)
WO (1) WO1994028391A1 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537932B1 (en) 1993-05-19 2009-05-26 Schering Corporation Antibodies that bind purified mammalian FLT3 ligands
JPH09501822A (ja) * 1993-05-19 1997-02-25 シェリング・コーポレーション 精製哺乳動物ｆｌｔ３リガンド並びにそのアゴニストおよびアンタゴニスト
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
US5789655A (en) * 1994-05-13 1998-08-04 The Regents Of The University Of California Transgenic animals expressing artificial epitope-tagged proteins
US6103694A (en) * 1995-07-21 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Method of decreasing radiation of radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
GB9519776D0 (en) * 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
CA2232865A1 (fr) 1995-10-04 1997-04-10 Immunex Corporation Facteur de stimulation flt3 de cellules dendritiques
US20030103988A1 (en) * 1995-10-26 2003-06-05 Leonard Chess Regulation of activated t cells by recognition of t cell receptor beta chains and major histocompatibility complex class ib molecules
US5849999A (en) * 1996-10-16 1998-12-15 The Mclean Hospital Corporation Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
AU7835898A (en) * 1997-06-17 1999-01-04 Immunex Corporation A method of enhancing antigen-specific peripheral immune tolerance
AU1705599A (en) * 1997-11-26 1999-06-15 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
WO1999038008A1 (fr) * 1998-01-23 1999-07-29 Prolifaron, Inc. Procedes et compositions d'identification de substances mimetiques de facteurs de croissance, de facteurs de croissance et d'inhibiteurs
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
US6649352B1 (en) * 1999-01-29 2003-11-18 Center For Molecular Medicine And Immunology Method of evaluating myelosuppressive state
US7112409B2 (en) * 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
DK1187852T3 (da) * 1999-05-19 2007-11-26 Merck Patent Gmbh Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK1842002A3 (en) 1999-08-09 2003-09-11 Lexigen Pharm Corp A fusion protein, a multi-function protein complex, a multi-function fusion protein, a nucleic acid, a cell, their use, method for preparing a fusion protein and method of targeting cytokines
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
WO2001036489A2 (fr) 1999-11-12 2001-05-25 Merck Patent Gmbh Formes d'erythropoietine dotees de proprietes ameliorees
ES2433011T3 (es) 1999-12-20 2013-12-05 Immunex Corporation Receptor TWEAK
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CN1527721A (zh) * 2000-09-12 2004-09-08 基因特罗生物治疗公司 含治疗性蛋白混合物的组合物及其生产方法
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
EP1351707B9 (fr) 2001-01-09 2012-01-25 Baylor Research Institute Traitements de maladies auto-immunes chez un sujet et techniques diagnostiques i in vitro /i
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
WO2002079415A2 (fr) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
CN1541113A (zh) * 2001-04-27 2004-10-27 �Ƹ��� 利用激活的t细胞使抗原提呈细胞成熟
KR100900166B1 (ko) * 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
US20030017529A1 (en) * 2001-06-27 2003-01-23 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US7070996B2 (en) 2001-08-31 2006-07-04 Rigel Pharmaceuticals, Inc. Production of cultured human mast cells and basophils for high throughput small molecule drug discovery
AU2002363322A1 (en) * 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1454138B1 (fr) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines a selectivite modulee
CA2480128A1 (fr) * 2002-03-26 2003-10-09 Immunex Corporation Procedes d'utilisation d'un ligand flt3 dans des protocoles d'immunisation
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
WO2004055056A1 (fr) 2002-12-17 2004-07-01 Merck Patent Gmbh Forme humanisee de l'anticorps de souris 14.18 (h14.18) se liant au gd2 et fusion de celle-ci avec il-2
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
AU2004252465A1 (en) * 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US20040254108A1 (en) * 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
AU2004289287A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
CA2547635C (fr) 2003-12-12 2016-02-09 Jeffrey Schlom Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
JP2007516984A (ja) * 2003-12-24 2007-06-28 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 治療用物質およびそのための用途
EP1699822B1 (fr) 2003-12-30 2008-04-23 MERCK PATENT GmbH Proteines de fusion de il-7 avec des segments d'anticorps, leur préparation et utilisation
WO2005063808A1 (fr) 2003-12-31 2005-07-14 Merck Patent Gmbh Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
PT1706428E (pt) * 2004-01-22 2009-12-29 Merck Patent Gmbh Anticorpos anticancerígenos com fixação de complemento reduzida
CN100404683C (zh) * 2004-05-27 2008-07-23 中国医学科学院基础医学研究所 一种人fl多核苷酸及其与人gm-csf联合基因治疗恶性肿瘤的用途
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP2008505650A (ja) * 2004-07-12 2008-02-28 ソリン・グループ・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータ ヒト細胞を増殖させるための装置及び方法
US8420611B2 (en) * 2004-08-12 2013-04-16 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
EP1819728B1 (fr) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Variants de l'il-7 a immunogenicite reduite
EP1860180A4 (fr) * 2005-02-23 2009-03-11 Found Biomedical Res & Innov Procédé d'amplification in vitro de cellule progénitrice endothéliale
US20090050204A1 (en) * 2007-08-03 2009-02-26 Illuminex Corporation. Photovoltaic device using nanostructured material
US7482165B2 (en) * 2005-08-24 2009-01-27 Beckman Coulter, Inc. Method of preventing white blood cell interferences to red blood cell measurements of a blood sample
US20070048254A1 (en) * 2005-08-24 2007-03-01 Mirus Bio Corporation Generation of dendritic cells
KR101397290B1 (ko) * 2005-12-30 2014-05-21 메르크 파텐트 게엠베하 감소한 면역원성을 가지는 항-ｃｄ19 항체
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
CA2646429A1 (fr) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. Inhibiteurs de la 8-heteroarylpurine mnk2 pour le traitement de troubles metaboliques
WO2007109583A2 (fr) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions et méthodes pour la prévention ou le traitement de maladie néoplasique chez un sujet mammalien
US8883493B2 (en) * 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
US8834409B2 (en) 2008-07-29 2014-09-16 Covidien Lp Method for ablation volume determination and geometric reconstruction
CA2681236A1 (fr) * 2008-10-24 2010-04-24 Mount Sinai School Of Medicine Of New York University Methodes et compositions pour le traitement de la fibrose
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
US10383924B2 (en) 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
CN102647989A (zh) * 2009-10-19 2012-08-22 特里施泰姆贸易(塞浦路斯)有限公司 采用重编程序的成熟成体细胞的治疗
EP2513311B9 (fr) 2009-12-18 2021-08-18 Bavarian Nordic A/S Production d'IFN-lambda par des cellules dendritiques conventionnelles et utilisations associées
US9012178B2 (en) 2010-08-05 2015-04-21 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
WO2012065755A1 (fr) 2010-11-19 2012-05-24 Bavarian Nordic A/S Production d'ifn-lambda par des lymphocytes b
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
HUE033279T2 (en) 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture
MX2014002533A (es) 2011-09-02 2014-08-26 Amgen Inc Producto farmaceutico y metodo de analisis de exposicion a la luz de un producto farmaceutico.
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
RU2619221C2 (ru) * 2012-03-28 2017-05-12 Кварримен Корпорейшн Иммортализованная стволовая клетка и лекарственная композиция и лекарственный препарат, содержащие ее в качестве активного ингредиента
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US20160024144A1 (en) 2013-03-14 2016-01-28 Amgen Inc. Removal of leaked affinity purification ligand
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US11130980B2 (en) 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
JP6732660B2 (ja) 2014-01-13 2020-07-29 アムジエン・インコーポレーテツド 組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節
EP3926051B1 (fr) 2014-06-04 2024-05-08 Amgen Inc. Procédés pour la récolte de cultures de cellules de mammifères
CA2968372A1 (fr) 2014-11-19 2016-05-26 Amgen Inc. Quantification de la fraction glycane dans des glycoproteines recombinantes
HUE049201T2 (hu) 2014-12-01 2020-09-28 Amgen Inc Eljárás glikoprotein glikántartalmának befolyásolására
US11097014B2 (en) * 2016-06-14 2021-08-24 University Of Cincinnati Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
US11850279B2 (en) 2016-07-13 2023-12-26 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
JP2020516654A (ja) 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US20210077832A1 (en) 2018-01-26 2021-03-18 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
WO2019160976A1 (fr) * 2018-02-14 2019-08-22 Viela Bio, Inc. Anticorps dirigés contre le ligand du récepteur 3 de la tyrosine kinase 3 du sarcome de mcdonough félin (fms) (flt3l) et leurs utilisations pour le traitement de maladies auto-immunes et inflammatoires
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN113645987A (zh) * 2019-03-28 2021-11-12 奥里尼斯生物科学股份有限公司 针对fms样酪氨酸激酶3(flt3)的嵌合蛋白和嵌合蛋白复合物
CA3136626A1 (fr) * 2019-04-12 2020-10-15 Emory University Compositions et procedes pour favoriser la cytotoxicite des cellules hematopoietiques
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
EP4232070A1 (fr) * 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Procédés d'induction de la mobilisation de cellules souches
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2023129974A1 (fr) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Génération de lignées de cellules avec site d'intégration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5057420A (en) * 1987-06-05 1991-10-15 Granada Biosciences, Inc. Bovine nuclear transplantation
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
JPH0611705B2 (ja) * 1988-02-10 1994-02-16 新技術事業団 血小板減少症治療剤
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5763266A (en) * 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5270458A (en) * 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5409825A (en) * 1991-04-09 1995-04-25 Indiana University Foundation Expansion of human hematopoietic progenitor cells in a liquid medium
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CA2122141C (fr) * 1991-10-23 2007-07-17 Shelly Heimfeld Methode de multiplication selective de cellules souches
WO1993009220A1 (fr) * 1991-11-06 1993-05-13 Correa Paulo N Milieu de culture cellulaire
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand

Also Published As

Publication number Publication date
AU683472B2 (en) 1997-11-13
US20030148516A1 (en) 2003-08-07
US6919206B2 (en) 2005-07-19
HU9503341D0 (en) 1996-01-29
CN1123574C (zh) 2003-10-08
FI955646A0 (fi) 1995-11-23
MY148148A (en) 2013-03-15
PL311756A1 (en) 1996-03-18
HUT74831A (en) 1997-02-28
JPH08511251A (ja) 1996-11-26
US5843423A (en) 1998-12-01
CA2162397C (fr) 2007-04-03
FI955646A (fi) 1996-01-23
CN1125479A (zh) 1996-06-26
WO1994028391A1 (fr) 1994-12-08
UA42726C2 (uk) 2001-11-15
KR100319359B1 (ko) 2002-07-31
NZ267541A (en) 1997-06-24
NO954735L (no) 1996-01-23
NO954735D0 (no) 1995-11-23
JP4028594B2 (ja) 2007-12-26
NO322373B1 (no) 2006-09-25
AU6987794A (en) 1994-12-20
US5554512A (en) 1996-09-10
CA2162397A1 (fr) 1994-12-08
BR9407073A (pt) 1996-08-27

Similar Documents

Publication Publication Date Title
US5843423A (en) Methods of stimulating hematopoietic cells with flt3-ligand
US7041282B2 (en) Ligands for flt3 receptors
US20110053863A1 (en) Methods of using flt3-ligand in the treatment of cancer
US6190655B1 (en) Methods of using Flt-3 ligand for exogenous gene transfer
US7045128B2 (en) Antibodies against flt3-ligand
US6630143B1 (en) Antibodies against flt3 ligand
US20140099710A1 (en) Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
JP4224624B2 (ja) 造血幹細胞または造血前駆細胞の増殖または生存を支持し得るポリペプチドおよびそれをコードするｄｎａ
JP4251983B2 (ja) 造血幹細胞または造血前駆細胞の増殖または生存を支持し得るポリペプチドおよびそれをコードするｄｎａ
US20090131634A1 (en) Method for Preparing Cell Fraction Containing Hemangioblasts
Takatsu et al. Interleukin 5 and its receptor
RU2220979C2 (ru) ПОЛИПЕПТИД ЛИГАНДА flt3 (ВАРИАНТЫ), ПОЛИНУКЛЕОТИД(ВАРИАНТЫ), ЭКСПРЕССИРУЮЩИЙ ВЕКТОР(ВАРИАНТЫ), ЛИНИЯ КЛЕТОК СНО (ВАРИАНТЫ), СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА ЛИГАНДА flt3 (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ)
MXPA94003806A (en) Ligands for receivers f
US20050059145A1 (en) Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
Friend Identification of a novel growth factor and the role of thymic stroma in hematopoiesis
He The role of the common gamma-c subunit of IL-2, IL-4, IL-7, IL-9, and IL-15 receptors in ligand-receptor interactions and lymphocyte development
IMHOF¹ et al. 6. THE ONTOGENY OF LYMPHOCYTES AND HOMING TO THE THYMUS